The cholinergic impairment is an early marker in Alzheimer's disease (AD), while the mechanisms are not fully understood. We investigated here the effects of glycogen synthase kinse-3 (GSK-3) activation on the cholinergic homoeostasis in nucleus basalis of Meynert (NBM) and frontal cortex, the cholinergic enriched regions. We activated GSK-3 by lateral ventricular infusion of wortmannin (WT) and GF-109203X (GFX), the inhibitors of phosphoinositol-3 kinase (PI3-K) and protein kinase C (PKC), respectively, and significantly decreased the acetylcholine (ACh) level via inhibiting choline acetyl transferase (ChAT) rather than regulating acetylcholinesterase (AChE). Neuronal axonal transport was disrupted and ChAT accumulation occurred in NBM and frontal cortex accompanied with hyperphosphorylation of tau and neurofilaments. Moreover, ChAT expression decreased in NBM attributing to cleavage of nuclear factor-jB/p100 into p52 for translocation into nucleus to lower ChAT mRNA level. The cholinergic dysfunction could be mimicked by overexpression of GSK-3 and rescued by simultaneous administration of LiCl or SB216763, inhibitors of GSK-3. Our data reveal the molecular mechanism that may underlie the cholinergic impairments in AD patients.
Introduction
Alzheimer disease (AD) is the most common type of dementia in the elderly. Although the pathogenesis is still elusive, a profound reduction of ACh level and selective loss of cholinergic neurons in specific brain regions have been proposed to be the primary cause for the cognitive impairment in AD patients [1, 2] . ACh is synthesized by choline acetyltransferase (ChAT) [3] and degraded by AChE [4] . Studies have shown that ChAT is the most specific indicator for monitoring the functional state of cholinergic neurons in nerve system. The activity of ChAT is decreased in the neocortex, which correlates positively with the severity of dementia in AD patients [5] . While the AChE may be compensatory decreased in the AD brains [6] , the treatments of AD patients so far have been dominated by the application of AChE inhibitors, which offers symptomatic relief by inhibiting ACh turnover and restoring synaptic level of ACh [7] . However, not all patients respond equally to the drugs or the cognitive benefit may be of limited duration, and the disease itself does not stop proceeding and irreversibly aggravates at last. Therefore, search for other target is of importance for preserving the cholinergic functions. Glycogen synthase kinase-3b (GSK-3b) has broad physiological and pathological functions, such as regulating glucose metabolism, regulating neurodevelopment as an important component of Wnt/ wingless signalling [8, 9] and phosphorylating tau at multiple AD-associated sites [10, 11] . Studies show that neurons undergoing granulovascular degeneration contain active GSK-3b [12, 13] that is localized in the pretangle neurons, dystrophic neurites and neurofibrillary tangles in the AD brains [14] . An increased level of active GSK3b coinciding both spatially and temporally with the progression of neurodegeneration has also been observed [15, 16] .
As all these studies suggest that GSK-3 and ChAT are both deeply involved in the AD pathology and symptom, it seems that there is a probable mechanism link of the activated GSK-3b with impaired cholinergic function in the AD brains. As the direct GSK-3b activator is still not commercially available, we have developed an indirect GSK-3b activation model by ventricular infusion of WT and GF-109203X (GFX), which activates GSK-3b via inhibiting the PI3-K and PKC, respectively, the kinases contribute to the phosphorylation GSK-3b at serine-9 and thus inhibit GSK-3b [17] . Using this rat model, we studied the effects of GSK-3b on cholinergic functions in the NBM and frontal cortex of the rat brains and the further molecular mechanisms.
Materials and methods

Animals and surgical procedures
Male Wistar rats (Grade II, weight 200-250 g, 4 months old) were supplied by Experimental Animal Central of Tongji Medical College. All animal experiments were performed according to the 'Policies on the Use of Animals and Humans in Neuroscience Research' revised and approved by the Society for Neuroscience in 1995, and the animal study was approved by the Medical Ethics Committee of our college.
Each rat was first anaesthetized by pentobarbital sodium (45 mg/kg, intraperitoneally) and placed on a stereotactic instrument with the incisor bar set 2 mm below the ear bars (i.e. flat skull). A 10-ll syringe (Hamilton) was stereotaxically placed into the left ventricle at the coordinates for bregma and dura of AP (-0.9), L (1.5) and V (4) and into the left NBM of AP (-1.4), L (2.5) and V (7) (in mm) after the scalp was incised and retracted. (WT, 100 lM) and GF-109203X (GFX, 100 lM) or simultaneously LiCl (Li, 200 mM) was injected into the left ventricle (10 ll, all from Sigma-Aldrich, St. Louis, MO, USA), and same volume of artificial cerebrospinal fluid (aCSF) containing 140 mM NaCl, 3.0 mM KCl, 2.5 mM CaCl 2 , 1.0 mM MgCl 2 , 1.2 mM Na 2 HPO 4 , pH 7.4 was injected as vehicle control [18] . The wild HA-tagged GSK-3b (GSK3b-HA) plasmid or GSK-3b adeno-associated virus (AAV, pAOV-CMVbGlobin-GSK3b-eGFP-3FLAG, NM_001146156) was injected into the Fig. 1 Activation of GSK-3 decreases ACh level in dialysates of NBM and frontal cortex. The microdialysis probes were implanted into the NBM and frontal cortex of the rats (A and B) at 30 min. after the left ventricular infusion of WT and GFX (W + G) or simultaneously combined LiCl (Li + W + G) or the vehicle. Then, the ACh level in the dialysates of NBM (C) and frontal cortex (D) was measured at 24 hrs after ventricular infusion. The Ser9-phosphorylated GSK-3b (pSer9-GSK3b) and the total GSK-3b were measured by Western blotting in NBM (E) and cortex (G) and relative quantitative analysis (F, H) at 24 hrs after the infusion. (LV, lateral ventricle; 3V, 3rd ventricle; D3V, dorsal 3rd ventricle; NBM (2 ll) of the rats. All surgical procedures were completed under sterile conditions, and penicillin (200,000 U, intramuscularly) was injected to prevent infection.
Microdialysis and high-performance liquid chromatography (HPLC) analysis
For measurement of ACh in NBM and frontal cortex, microdialysis and HPLC were performed. A microdialysis probe (CMA 11, Carnegie Medicine, Stockholm, Sweden) with 3.0 mm long of dialysis membrane (O.D., 0.24 mm; cut-off = 20 kDa) was implanted into the left NBM at the coordinates for bregma and dura of AP (-1.4), L (2.5), V (7) and frontal cortex of AP (2.5), L (1.0), V (3.5) (in mm) according to the stereotaxic atlas of Paxinos and Watson (Fig. 1A and B) 30 min. after stereotaxic infusion. The implanted probes were perfused with Ringer solution (147 mM NaCl, 4.0 mM KCl, 2.4 mM CaCl 2 , pH 7.0) containing 10 lM neostigmine to prevent degradation of ACh, at a perfusion rate of 2 ll/ min. controlled by a micro infusion syringe pump (CMA 102; Carnegie Medicine). The position of the microdialysis probe was verified by histological procedures at the end of each experiment. Recovery rate of ACh of the microdialysis probe in vitro is over 96%. The analysis of ACh was carried out at 24 hrs after probe implantation in freely moving animals according to the method described previously [16] . In brief, collected samples passed through a reverse-phase analytical column before entering an immobilized enzyme reactor column, where hydrogen peroxide was produced from ACh. Hydrogen peroxide was detected at a platinum electrode held at a potential of +500 mV relative to an Ag+/ AgCl reference electrode. The generated current created a chromatogram peak that was recorded on a flat-bed recorder and processed by a software program. The chromatogram peak areas are proportional to ACh content in each collected sample. The ACh levels were calculated and then expressed as qmol/40 ul perfusate for each collected sample.
ChAT and AChE activity assay
To determine the activities of ChAT and AChE, tissues of NBM and frontal cortex were homogenized in 1% Triton X-100 at a ratio of 10 ml/g tissue and centrifuged at 4°C 10,000 g for 15 min. The supernatants were used for determination of the activities of ChAT and AChE by the radioisotopic method of Fonnum and colorimetric assay, respectively, as previously described [18] .
Nuclear protein extraction and Western blot NBM extracts were prepared using buffer A [19] . Preparation of cytoplasmic and nuclear fractions was performed as previously described [20] . The antibodies employed are listed in Table 1 . Western blotting was performed as described previously [21] . In brief, the NBM, frontal cortex or cell extracts were separated by 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and the protein bands were electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes and immunoblotted with the primary antibodies. 
Reverse transcription polymerase chain reaction (RT-PCR)
For RT-PCR, the rats were decapitated at 24 hrs after the brain infusion and the tissues from the NBM region (50-100 mg) were dissected, lysed by 1 ml Trizol solution (Gibco, Gaithersburg, MD, USA) to extract the total RNA. The total RNA ( 
Cell studies
The human embryonic kidney 293 (HEK293) cells were cultured in DMEM supplemented with 10% foetal bovine serum at 37°C in 5% CO 2 .
The cells were transiently transfected with the GSK-3b-HA plasmid using lipofectamine 2000 transfection kit according to the manufacturer's instructions.
Primary neuronal cultures were prepared from embryonic 17 of Sprague-Dawley rat as described previously with some modifications [22] . Briefly, basal forebrain was dissected from the whole-brain tissues and digested in 0.25% trypsin (Invitrogen, Grand Island, NY, U.S.A.) at 37°C for 15 min. Dissociated neurons were plated into poly-D-lysine (Sigma-Aldrich) coated coverslips in 12-well plate. After 7 days, we added 1 ul GSK-3b AAV or vector virus in relative wells and cultured for an additional 7 days. After fixing by 4% paraformaldehyde for 30 min., we carried out the immunofluorescence staining.
For fluorescence recovery after photobleaching (FRAP) experiments, wild Neuro-2a (N2a) cells were seeded in 4 cm dishes in DMEM medium with 10% foetal bovine serum (all from Gibco) and transfected with composite rat ChAT-GFP-expressing plasmid (pEGFP-C2-RChAT) when cells coved 60% area. Thirty-six hours after transfection, we treated cell with DMSO or 1 lM WT and GFX or simultaneously combined 5 lM SB216763 (all from Sigma-Aldrich) for 1 hr, then replaced medium by DMEM (without carbonate and phenol red), and supplemented with 20 mM HEPES. Imaging was performed with a Zeiss equipped with a preheated 37°C chamber using the 488 nm Ar laser. Ten prebleach images were acquired with 1% laser intensity, followed by bleaching with 100% laser intensity. Bleaching was targeted to regions in long branching. After bleaching, 150 images were taken with a scanning speed of 60 Hz with 1% laser intensity. FRAP recovery rate was determined after full-scale normalization. Rate constant, recovery half time and mobile fraction of pEGFP-C2-RChAT were calculated by the software for FRAP. The fluorescence recovery intensity was normalized to the prebleach fluorescence intensity.
The rat brain studies of morphology At 24, 48, 72 and 96 hrs following the ventricular infusion of WT and GFX, the rat brains were fixed in situ for 20 min. by transcardial perfusion with Zamboni's solution. Then, the brains were isolated and fixed in the same solution for another 12 hrs at 4°C and sliced coronally about 20 lm thickness with a freezing microtome (CM1900, Leica Microsystems, Wetzlar, Germany). For immunohistochemistry, the sections containing NBM and frontal cortex were incubated for 48 hrs at 4°C with primary antibodies PHF-1 (1:250), pS396 (1:500) and ChAT (1:500). The slices were developed with HistostainTM-SP kits (ZEMED, South San Francisco, CA, USA) and visualized with 3,3 0 -Diaminobenzidine (DAB) staining.
For double-labelling immunofluorescence, the brain sections containing NBM collected under identical conditions. After blocking with 3% BSA for 1 hr, the sections were then incubated for 48 hrs at 4°C with a mixture of anti-non-phosphorylated neurofilament (SMI33) and antiChAT or anti-phospho-tau at Ser396 epitope (pS396) antibodies. Then, the immunoreactivity was probed with relevant conjugated secondary antibodies. Fluorescent-stained sections were examined using an Olympus FV500 confocal laser scanning microscope (Olympus, Tokyo, Japan).
The Bielschowsky's silver staining was carried out as described [23] . Briefly, the sections were placed in 3% silver nitrate solution (37°C) for 30 min. in dark and reduced for 5 min. with 10% formaldehyde. Then, the sections were treated with ammonium silver alcohol solution for 5 min. and soaked in 8% formaldehyde until the sections become dark brown.
The Nissl staining was carried according to the standard procedure [16] . To further assess any possible atrophy and neuronal loss, magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) were applied [16] . For transmission electron microscopy (TEM), the ultrathin sections stained with uranyl acetate and lead citrate were observed by TEM.
Statistical analysis
Data were expressed as x AE SD and analysed using SPSS 20.0 statistical software (SPSS Inc., Chicago, IL, USA). The one-way ANOVA procedure followed by LSD's post hoc tests was used to determine the different means among groups (P < 0.05).
Results
Activation of GSK-3 decreases ACh level in NBM and frontal cortex measured by microdialysis and HPLC
To explore the role of GSK-3 in cholinergic function, we implanted the microdialysis probes into different brain regions and measured ACh level in the dialysate after ventricular infusion of WT and GFX or simultaneously combined LiCl, an inhibitor of GSK-3. We found that the ACh level in the dialysates decreased prominently at 24 hrs after ventricular infusion of WT and GFX, simultaneous infusion of lithium attenuated the reduction of ACh level in NBM (Fig. 1C ) and the frontal cortex (Fig. 1D) .
To validate the increase of GSK-3 activity, we measured the relative levels of Ser9-phosphorylated GSK-3b (pSer9-GSK-3b, inactive form) and the total GSK-3b. We found that the level of pSer9-GSK-3b decreased with unchanged total GSK-3b level in NBM (Fig. 1E ) and the frontal cortex (Fig. 1G) after infusion of WT and GFX by quantitative analysis (Fig. 1F and H) .
Activation of GSK-3 inhibits ChAT but not AChE in NBM and frontal cortex
Choline acetyltransferase and AChE are, respectively, responsible for the biosynthesis and degradation of ACh. Therefore, we measured the activity of ChAT and AChE after infusion of WT and GFX for 24 hrs. The activity of ChAT in both NBM and frontal cortex was decreased prominently ( Fig. 2A) , whereas the activity of AChE was not altered (Fig. 2B) . These data suggest that the inhibition of ChAT is involved in the decreased ACh level induced by GSK-3 activation instead of AChE.
Activation of GSK-3 causes axonal accumulation of ChAT in cortex neurons
To explore the underlying mechanisms involved in the decreased ChAT activity, we first detected the expression level of ChAT in the frontal cortex. Unexpectedly, we did not observe significant decrease of ChAT level by Western blotting with internal control of b-actin (Fig. 3A and B) . Then, we detected the cellular distribution of ChAT by immunohistochemistry staining. We observed that ChAT was uniformly distributed in both cell bodies and axons in rats of sham group (Fig. 3C, sham) ; however, an enhanced ChAT staining was detected in the distant axonal swellings (Fig. 3C, black arrow) . The accumulation of ChAT was especially prominent at 72 and 96 hrs after the infusion of WT and GFX (Fig. 3C, 72 and 96 hrs) .
To validate the axonal pathology, we used Bielschowsky's silver staining. Enhanced argyrophil substances were shown in the cell bodies and proximal neurites at 24 hrs after infusion of WT and GFX, and the argyrophil substances migrated to the apical neurites and massive tangle-like structures were detected in the cortical neurons at 72 and 96 hrs after WT and GFX infusion (Fig. 3D, silver staining) . Similar pattern of distribution was found when we detected with antibodies of phosphorylated tau by immunohistochemistry (Fig. 3D, pS396 and PHF-1). The distribution of both argyrophil tangle-like structures and phosphorylated tau coincided with the progression of axonal swellings, especially at 72 hrs, which indicated that ChAT transport impairment might be due to these tauopathies. Fluent axonal transportation of ChAT is closely associated with its normal physiological function on ACh synthesis [3] ; hence, these data together contributed to the mechanism of decreased ACh level observed in the frontal cortex.
Activation of GSK-3 inhibits expression and causes accumulation of ChAT in NBM neurons without cell death
To explore the underlying mechanisms involved in the decreased ChAT activity in NBM, we detected the expression and distribution of ChAT. By immunohistochemical staining, a remarkably decreased immunoreactivity of ChAT at the neuronal processes (Fig. 4A) and number of ChAT-positive cells were detected at 24 hrs after infusion of WT and GFX (Fig. 4A and D) . Additionally, a prominently decreased ChAT level was detected by Western blotting (Fig. 4E) . By immunohistochemistry, we also found enhanced ChAT staining in the cell bodies and axonal swellings in NBM (Fig. 4A and B) . To explore the possible contents in the axonal swellings, we used TEM. Significant axonal swellings, including abnormal accumulation of mitochondria, vesicles, organelles and dense bodies, were observed in both unmyelinated and myelinated neurons (Fig. 4C) .
Moreover, we infected NBM neurons in vivo (Fig. 5A ) and primary neurons in vitro (Fig. 5B) with GSK-3b AAV, and also found reduced ChAT level. These results confirmed that both activation and overexpression of GSK-3 down-regulated ChAT expression level in cholinergic neurons.
As the number of ChAT-positive neurons was significantly decreased in NBM ( Fig. 4A and D) , we also examined whether this decline was caused by cell death. We first did Nissl staining and found that the total cell number in NBM was not altered by stereological analysis at 24 hrs after ventricular infusion of WT and GFX (Fig. 6A) . We also used MRI and MRS to detect any possible atrophy or cell loss (Fig. 6B-D) . The T 2 -weighted images in the focal area inside the brain were unchanged, and no visible ventricle augmentation or atrophy in NBM was detected by MRI (Fig. 6B) . Similarly, no obvious alteration in T 2 value and the ratio of NAA/tCr were observed after WT and GFX infusion measured by MRS (Fig. 6C and D) , and consistent result was found in frontal cortex (Fig. 6B-D) . These data indicate that the loss of ChAT-positive neurons is consequent with the decreasing ChAT expression rather than a general cell death.
To verify the axonal transport impairment, we used FRAP to detect whether WT and GFX treatment affected the transport process of the expressive ChAT in the transfected N2a cells with pEGFP-C2-RChAT plasmid. For FRAP experiments described in method, we could observe the fluorescence in marked area disappeared (bleach) and slowly recovered (post-bleach) in N2a cells' long processes (Fig. 7A) . The rate constant of the WT and GFX group was significantly lower than that of the control group (Fig. 7B) , and the half recovery time was significantly longer than that of the control group for 10 sec. (Fig. 7C) . These data indicate that the transport rate of ChAT in N2a cells is decreased after treatment of WT and GFX. In order to further prove the inhibition of ChAT transport is caused by GSK-3 activation, we gave WT and GFX treatment with the GSK-3 inhibitor SB216763 to N2a cells simultaneously. The results showed that the rate constant increased significantly after SB216763 treatment, but did not return to the control group level (Fig. 7B) . The fluorescence recovery time decreased to about 8 sec., but still slightly higher than the control group (Fig. 7C) . The mobile fraction dynamics of the three groups was not significantly different (Fig. 7D) . The record of the fluorescence change with time curve also showed that the fluorescence intensity of WT and GFX infusion group (Fig. 7E, W + G) represented the slowest recovery, while the recovery rate of simultaneously SB216763 infusion group (Fig. 7E , SB + W + G) was obviously faster than it but still slower than the control group (Fig. 7E, DMSO) , which indicating that SB216763 could partly reverse the inhibitory effect of GSK-3 on the transport of ChAT. These results confirmed that GSK-3 activation can specifically inhibit the ChAT transport in the N2a cell processes.
Activation of GSK-3 decreases mRNA level of ChAT through the phosphorylation and cleavage of nuclear factor-jB in NBM As ChAT level decreased in NBM neurons, we found the mechanism by series of experiments as follows. The tissues from NBM region were dissected at 24 hrs after ventricular injection, and the extracts of total RNA were prepared for RT-PCR test. We found that the mRNA of ChAT obviously decreased after WT and GFX infusion compared with Vehicle treatment, with b-actin as internal control (Fig. 8A) . To explore the underlying mechanisms involved in the decreased ChAT mRNA level induced by GSK-3 activation, we measured the cleavage of nuclear factor-jB (NF-jB)/p100, a factor can inhibit synthesis of ChAT in the nucleus through its degradation product NF-jB/p52 [24] . We observed that the level of p52 increased prominently accompanying with a decreased p100 in the total NBM extracts with WT and GFX exposure for 24 hrs (Fig. 8B, total extracts) . Similar results were found in both cytosolic ( Fig. 8B) and nuclear (Fig. 8B) fractions. Relative quantitative analysis was also shown (Fig. 8C) . The results suggest an increased cleavage of p100 into p52, which consequently facilitates the translocation of p52 into nuclei and inhibits ChAT synthesis.
Phosphorylation of p100 at Ser866/870 triggers the cleavage itself [25] . To explore the involvement of p100 phosphorylation in its cleavage in present study, wild GSK-3b-HA was expressed in HEK293 cells and the phosphorylation level of p100 was measured. We found that the phosphorylated p100 at Ser866/870 significantly increased in the cells transfected with GSK-3b-HA plasmid (Fig. 8D) , suggesting that p100 phosphorylation was concerned with the increased GSK-3b activity, which may underlie the increased cleavage of p100.
Increased GSK-3 activity causes ChAT accumulation in cell body through modulating phosphorylation level of tau and neurofilaments in NBM
The simultaneous cytoplasmic expression of GSK-3b and ChAT was observed in NBM neurons of normal rat (Fig. 9A) , which gave support to the modulation effect of GSK-3b to ChAT. To explore the possible mechanism of ChAT transport retardation in NBM, we injected directly WT and GFX or simultaneously combined LiCl or GSK-3b-HA plasmid into the NBM, the region with enriched cholinergic neurons. By immunofluorescent staining, we found increased phosphorylated tau (Fig. 9B, pS396 ) and decreased nonphosphorylated neurofilaments (Fig. 9B and C, SMI33 ) at 24 hrs after WT and GFX infusion. The ChAT distributed evenly in the neurons and well merged with the non-phosphorylated neurofilaments in vehicle group, while the cytoplasmic accumulation of ChAT was detected in WT and GFX group (Fig. 9C, ChAT) . It suggests that ChAT distribution is related to the phosphorylation level of tau and neurofilaments.
Simultaneous application of lithium partially improved the abnormal cellular distributions of ChAT and phosphorylation level of tau and neurofilaments (Fig. 9B and C 
By direct injection of GSK-3b-HA plasmid into the NBM, we observed that the neurons expressing HA-tagged GSK-3b showed accumulation of ChAT (Fig. 9D, blue arrow) , but the accumulation was not observed in the neurons without expression of the GSK-3b in the same visual field (Fig. 9D, yellow arrowhead) , which demonstrated the GSK-3b-dependent ChAT misdistribution. 
Discussion
Impairment of cholinergic neurotransmission is a well-established fact in AD patients, but the upstream factor leading the impairment is still not understood. Using a microdialysis system, we found in the present study that activation of GSK-3 by ventricular infusion of WT and GFX led to a remarkable reduction of ACh in the dialysates of NBM and frontal cortex in rats. As ChAT and AChE are, respectively, the rate-limiting enzymes for the synthesis and degradation of ACh, we detected the activity of the two enzymes and only the decreased ChAT was observed, suggesting that GSK-3 reduces ACh level through interrupting the synthesis but not the degradation system. Further studies demonstrated that activation of GSK-3 caused severe axonal accumulation of ChAT in both frontal cortex and NBM regions due to abnormal phosphorylation of tau and neurofilaments and suppressed the expression of ChAT in NBM neurons. Our data provide direct evidence showing that activation of GSK-3 reduces ACh level through interrupting the axonal transport or/and expression of ChAT.
Increasing evidences imply that GSK-3 may be involved in cholinergic function. The expression of GSK-3b is restricted in the neurite structures of the basal forebrain cholinergic neurons in young rats, whereas it is confined to the cell bodies in the aged rats [26] . The degeneration of forebrain cholinergic neurons induced by cholinergic immunotoxin 192-IgG saporin is mediated by an increased GSK-3b activity and the GSK-3b inhibitor LiCl can partly protected cholinergic neurons [27] . GSK-3b can phosphorylate and inactivate pyruvate dehydrogenase (PDH), which regulates ACh synthesis by converting pyruvate into acetyl-CoA in mitochondria. In cholinergic neurons, Ab impairs ACh synthesis through inactivating PDH by GSK-3b [28] . In PC12 cells, inhibition of PI3-K blocks the nerve growth factor-induced elevation of ACh level that may involve GSK-3 activation [29] . Furthermore, activation of GSK-3 and suppression of cholinergic function have been observed in the AD brains [10, 30] . Based on these reports and our current observations, we propose that GSK-3 activation may be upstream for the damnified ACh synthesis system. As is well-known, some other neurotransmitters were involved in the AD pathogenesis including dopamine, 5-hydroxytryptaminem, glutamate, noradrenaline, c-aminobutyric acid and so on. However, the relationship between these neurotransmitters and GSK-3 and definite mechanism are not elucidated. To our knowledge, only dopamine [31] and 5-hydroxytryptamine [32] showed primary regulatory links, which deserved more research.
Choline acetyltransferase plays a crucial role in maintaining the ACh level in the nerve terminals. In primary neuronal cultures, the alteration in ACh synthesis parallels change of ChAT activity independent of high-affinity choline transport [33] . It is well recognized that a normal axonal transport is the precondition to ensure ChAT transport from the cell body to the axon terminal, and thus to catalyze ACh synthesis at the terminals [3] . In present study, we observed severe accumulation of ChAT in the axonal swellings in both frontal cortex and NBM neurons upon activation of GSK-3, suggesting impairment in axonal transport of ChAT (Fig. 10) .
The neurofilament proteins are normally synthesized in cell bodies and transported into and through axons by axonal transport [34] . There is evidence that this transport of neurofilaments is impaired in numerous neurodegenerative diseases due to the aberrant phosphorylation, aggregates and subsequent accumulation [35] . GSK-3 has been shown responsible for the neurofilaments phosphorylation resulting in impaired axonal transportation [36] . Additionally, our previous study has found that non-phosphorylated neurofilaments are prerequisite for unimpeded ChAT axonal transportation in rat striatum. The GSK-3 activation decreases the level of non-phosphorylated 'individual' neurofilaments and leads them to form more 'bundle' ones, which will be more difficult to be transported to the neuronal distal end [18] . Similarly, we found non-phosphorylated neurofilaments-dependent well-balanced distribution and transport of ChAT in NBM in present study, which further confirms the involvement of neurofilaments in mechanism of ChAT transport deficit (Fig. 10) .
Furthermore, GSK-3 also phosphorylates tau, which is well-known for disrupting microtubule assembly and axonal transport. Elevated tau phosphorylation decreases its microtubule binding and bundling and increases the number of motile tau particles, which affects the axonal transport [37] . The tau phosphorylation mediated by GSK3b is associated with proper anterograde transport [38] . Therefore, we speculate that hyperphosphorylation of tau induced by GSK-3 activation may be involved in the impaired axonal transport of ChAT (Fig. 10) . In present study, we indeed found tau hyperphosphorylation in neurons of NBM, which is well related to the ChAT transport deficit. Additionally, it is also noticed that the ChAT swellings became more severe in the distal end of the frontal cortical neuronal axons that were in parallel with the appearance of numerous tangle-like argyrophil structures at 72 and 96 hrs after ventricular infusion WT and GFX; however, there was no obvious cell loss although the pathology was apparent. This observation illustrated that the tanglelike structures by formation of the hyperphosphorylated tau destroyed the regular ChAT transportation without cell death, which is in consistent with that seen in Huntington disease [39] .
GSK-3 affects the expression level of several synaptic structural proteins, including synapsin I, PSD93, NMDA receptor 2A/B [40] . In the present study, we also observed that activation of GSK-3 suppressed the expression of ChAT in the NBM, source of cholinergic systems from the basal forebrain. Then, we further explore how GSK-3 activation affects the expression of ChAT. It has been reported that the cleavage of NF-jB from p100 to p52 and the nuclear translocation of p52 negatively regulate ChAT expression [24] , and the cells with GSK-3b deficits fail to activate an NF-jB-dependent reporter gene efficiently [41] . To explore the involvement of NF-jB processing in the GSK-3-induced inhibition of ChAT expression, we measured NFjB subunit level. The significantly decreased level of p100 and Fig. 10 Schematic diagram of the underlying mechanism of cholinergic function modulation by GSK-3 activation. (A) ChAT is synthesized in the cell body of cholinergic neurons and transported to the synaptic terminals along the microtubules and neurofilaments for catalyzing the biosynthesis of ACh. GSK-3 was activated via dephosphorylation at Ser9 epitope or overexpression in our present study; then, the microtubules and neurofilaments were hyperphosphorylated (B), which resulted in microtubule stability decline and neurofilaments aggregation (C). Both morphological abnormity prevented the smooth ChAT transport and led to the swelling formation in the axons, which correspondingly decreased the ChAT concentration in the neurite terminals and down-regulated the ACh level ultimately (C). Activated GSK-3 phosphorylated NF-jB/p100 and promoted its cleavage into p52. The active p52 migrated into the nucleus and inhibited mRNA level of ChAT (C and D). Our experiments directly illustrated the underlying mechanism about regulatory relationship between GSK-3 and ChAT. increased level of p52 as well as nuclear translocation were observed after ventricular infusion of WT and GFX. These results suggest that GSK-3 may stimulate p100 processing and p52 nuclear translocation resulting in inhibition of ChAT expression (Fig. 10) . A previous study demonstrates that subtype of NF-jB can be phosphorylated by many kinases, including GSK-3b [42] . Moreover, NF-jB/p100 may be phosphorylated at Ser866/870 leading to trigger the cleavage itself [25] . To confirm the role of GSK-3 in phosphorylating p100 and explore the mechanism of p100 cleavage, we transfected GSK-3b plasmid into the HEK293 cells and found prominently increased level of the phosphorylated p100 at Ser866/870 epitopes.
Taken together, we have found in the present study that activation of GSK-3 reduces ACh level in both NBM and frontal cortex of rat with the mechanisms involving disruption of axonal transport and suppression of ChAT expression (Fig. 10) .
